Biotechnology - Rare diseases, Respiratory and Pulmonary


Popular Filters

The case for Insmed's CF drug candidate Arikace; analysts' views


The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

FTC files Amicus Brief, saying improper use of restricted drug distribution programs may impede generic competition


The US Federal Trade Commission has filed an amicus brief in the US District Court for the District of…

ActavisActelionApotexBiotechnologyGenericsLegalNorth AmericaRare diseasesRespiratory and PulmonaryRoxaneTracleerZavesca

Gilead abandons development of PAH drug cicletanine


US biotech firm Gilead Sciences (Nasdaq: GILD), the world leader in HIV/AIDS drugs, has discontinued…

BiotechnologycicletanineGilead SciencesRare diseasesResearchRespiratory and Pulmonary

Germany’s IQWIG negative on InterMune’s Esbriet


US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency…

BiotechnologyEsbrietEuropeInterMuneRare diseasesRegulationRespiratory and Pulmonary

Company Spotlight



Back to top